S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB-B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML
HemaSphere | August 21, 2023 | Volume: 7 | Issue: S3 | Pages: e2941723
10.1097/01.hs9.0000967904.29417.23